DeCure for Ehlers-Danlos syndrome, dermatosparaxis type
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for Ehlers-Danlos syndrome, dermatosparaxis type — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEhlers-Danlos syndrome, dermatosparaxis type maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ehlers-danlos syndrome, dermatosparaxis type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 2021 review of hypermobile EDS (hEDS) in women identifies five primary dermatological changes: soft skin, atrophic cutaneous scars, piezogenic papules, hyperextensive stretchability, and haematomas. The review also notes livedo reticularis and elastosis perforans serpiginosa as additional skin manifestations. No treatment data are provided; the paper only lists possible consequences and treatment options without reporting outcomes.
A 1950 case report repeats the classic triad of dermatorrhexis (fragilitas cutis), dermatochalasis (laxitas cutis), and arthrochalasis (laxitas articularis) originally described by Ehlers and Danlos. The authors state that not all reported cases satisfied these three criteria. No treatment or outcome is discussed.
A 1979 report describes a 34-year-old woman with Ehlers-Danlos features strictly limited to the skin and subcutaneous tissue of the left shoulder, beginning at age 22 with subcutaneous nodules and progressing to hyperextensibility over five years. The case notably lacked joint hyperextensibility, bleeding tendency, scar formation, or systemic components. No treatment is mentioned.
A 2024 case report describes an 18-year-old Iranian woman with Ehlers-Danlos syndrome who presented with multiple purple nodules (0.5–1.5 cm) on the proximal lower limb, confirmed as dermatofibromas on biopsy. Physical examination revealed hyperextensible and fragile skin, wide atrophic scars, joint and finger hypermobility, swan neck deformities, knee nodules, and striae alba. She had asthma and atopic dermatitis but no family history. The authors state this combination of multiple dermatofibromas with Ehlers-Danlos syndrome had not been reported before. No treatment or outcome is given.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Women’s Dermatology · 2021 · 13 citations · open access
The dermatological aspects of hEDS in women
AbstractEhlers-Danlos syndrome (EDS) is a group of inherited connective tissue disorders that may present with a wide range of multisystemic symptoms. Hypermobile EDS, one of 13 identified subtypes of EDS, is the only variant without a known associated genetic mutation. A review of the literature suggests the five primary dermatological changes associated with hypermobile EDS are soft skin, atrophic cutaneous scars, piezogenic papules, hyperextensive stretchability, and hematomas. Our paper will address these cutaneous manifestations and delve into how they affect patients (primarily women). Possible consequences and treatment options for these different dermatological changes, as well as other skin manifestations such as livedo reticularis and elastosis perforans serpiginosa, will also be further explored.
AbstractWe report this case of the Ehlers-Danlos syndrome because of the general interest such a case presents to the practitioner of medicine. This disease process is not a rarity, and yet few cases have been reported in which all components of the syndrome were present. Early descriptions of the syndrome were made by Ehlers, by Cohn and by Danlos.<sup>1</sup>Since that time, many more cases have been reported, a larger proportion now coming from the American literature. In 1936 Ronchese<sup>2</sup>reviewed the literature, finding 27 previous cases and adding 3 of his own. Through this review it was learned that not all cases previously reported satisfied the criteria originally prescribed by Ehlers and Danlos, namely (1) dermatorrhexis (fragilitas cutis), (2) dermatochalasis (laxitas cutis) and (3) arthrochalasis (laxitas articularis). Speculation still exists concerning the etiology of this disease. The histopathologic picture varies according to the authors who
AbstractA 34-year-old woman had the cutaneous features of the Ehlers-Danlos syndrome, which was strictly limited to the skin and subcutaneous tissue in the region of the left shoulder. The disorder started at approximately age 22 with the development of subcutaneous nodules. Hyperextensibility of the skin in this region developed within the subsequent five years. There was a notable lack of the usually associated joint hyperextensibility, bleeding tendency, scar formation, or the serious systemic components of the Ehlers-Danlos syndrome. (<i>Arch Dermatol</i>115:332-333, 1979)
Journal of Medical Case Reports · 2024 · 0 citations · open access
Multiple dermatofibromas in a patient with Ehlers–Danlos syndrome: a case report
AbstractBACKGROUND: Dermatofibromas, also known as benign fibrous histiocytomas, are among the most common cutaneous soft-tissue lesions. Association of multiple dermatofibromas with some diseases was described and it has not been reported with Ehlers-Danlos syndrome before. We present a case with Ehlers-Danlos syndrome and multiple dermatofibromas. CASE PRESENTATION: An 18-year-old Iranian woman presented with multiple purple nodules ranging from 0.5 to 1.5 cm in diameter, which were mobile and located on the proximal part of the lower limb. The dimple sign of these lesions was positive. During the physical examination, several features suggestive of Ehlers-Danlos syndrome were observed, including hyperextensibility and fragility of the skin, wide atrophic scars on the upper limb, hypermobility of joints and fingers, swan neck deformities of the digits, nodules on the knee, and striae alba on the leg. The patient was previously unaware of having Ehlers-Danlos syndrome. She had a history of asthma and atopic dermatitis. Family history was negative. A biopsy of the nodular lesions was performed, and the findings confirmed the diagnosis of dermatofibromas. CONCLUSION: We describe a patient with Ehlers-Danlos Syndrome who presented with multiple dermatofibromas. To our knowledge, this combination of findings is a previously unreported occurrence.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
